Bluebird Bio to Be Acquired by Carlyle Group, SK Capital
Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.
Hosted on MSN1d
No OS Boost With Palbociclib and Endocrine Therapy in Premenopausal Breast Cancer
No improvement in overall survival (OS) was observed with palbociclib (Verzenio) plus endocrine therapy versus capecitabine ...
ncbiotech.org1d
From Classroom to Career: how NCCU’s BRITE program transformed one student’s path
The BRITE program and its partnerships with local universities provided Udemadu with critical hands-on training in cell culture and lab techniques. This provided a strong foundation that made his ...
TMCnet2d
NAYA Biosciences Announces Nomination of New Board Members
NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today ...
EMD Group Holding disputes $33.2M federal tax lien notice
EMD Group Holding Inc. has received a federal tax lien notice from the Internal Revenue Service indicating it owes over $33.2 ...
Merck KGaA to replace two executives with company veterans
Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...
EurekAlert!4d
Radiation plus combination immunotherapy may help preserve bladder in some patients with muscle-invasive bladder cancer
Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...